Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof
OwnerSampath Parthasarathyinventor
Life of this patent
Estimating the term…
Abstract
Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hypertension, diabetes, dyslipidemia, renal insufficiency, myocardial infarction, stroke, atherosclerosis, and the target organ damage that accompanies these various diseases and disorders, are further provided. The compounds are useful in improving vasodilation, reducing low-density lipoprotein oxidation, and reducing inflammation in a subject.
Claims17
A compound having the Formula (I):
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- or a pharmaceutically acceptable salt or solvate thereof.
3-14. (canceled)
A compound having the Formula (XV):
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCHCH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3;
- or a pharmaceutically-acceptable salt or solvate thereof.
A method for increasing vasodilation, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method for reducing low-density lipoprotein oxidation, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method for reducing inflammation, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method for treating hypertension, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method for treating dyslipidemia, comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method for improving renal insufficiency or slowing the deterioration of kidney function comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
A method of reducing or preventing the progression of microalbuminuria in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a compound selected from the group consisting of the following Formulas (I) and (XV), or pharmaceutically acceptable salts or solvates thereof:
- wherein:
- m is an integer from 1 to 2;
- n is an integer from 1 to 10;
- R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, and tert-butyl;
- and
- R3 is selected from the group consisting of COOH, COOCH3, COOCH2CH3,
- wherein:
- R1 and R2 are independently selected from the group consisting of H, CH3, and tert-butyl;
- and
- R3 is selected from the group consisting of CH2CHCH2CH2COOCH3, CH2CHCHCHCHCOOH, and CHCHCHCHCOOCH2CH3.
Dependencies are inferred from the claim text.